Prospective economic evaluation of phase III trial comparing irinotecan with infusional 5-FU in patients with advanced colorectal cancer

被引：0
|
作者：
Schmitt, C
Jolain, B
Van Cutsem, E
机构：
[1] UZ Gasthuisberg, Leuwen, Belgium
[2] Rhone Poulenc Rorer, Antony, France
[3] ARCOS, Issy Les Moulineaux, France
来源：
MEDICAL DECISION MAKING | 1998年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：484 / 484
页数：1
相关论文
共 50 条
  • [31] Randomized phase II study of combined infusional leucovorin sodium (LVNa) and 5-FU versus the sequential administration of leucovorin calcium (LVCa) followed by 5-FU with irinotecan or oxaliplatin in patients (pts) with metastatic colorectal cancer (mCRC)
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezael
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] A PROSPECTIVE TRIAL OF 5-FU AND BCNU IN THE TREATMENT OF ADVANCED GASTRIC-CANCER
    JAMIESON, GG
    GILL, PG
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1981, 51 (01): : 16 - 19
  • [33] Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: A randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).
    Zhang, Rong-xin
    Lin, Jun-zhong
    Chen, Gong
    Li, Li-ren
    Lu, Zhen-hai
    Ding, Pei-Rong
    Wu, Xiao Jun
    Wan, Desen
    Pan, Zhi-zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
    Sadighi, Sanambar
    Mohagheghi, Mohammad Ali
    Montazeri, Ali
    Sadighi, Zahra
    BMC CANCER, 2006, 6 (1)
  • [35] Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
    Sanambar Sadighi
    Mohammad Ali Mohagheghi
    Ali Montazeri
    Zahra Sadighi
    BMC Cancer, 6
  • [36] Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
    von Weikersthal, Ludwig Fischer
    Schalhorn, Andreas
    Stauch, Martina
    Quietzsch, Detlef
    Maubach, Peter A.
    Lambertz, Helmut
    Oruzio, Daniel
    Schlag, Rudolf
    Weigang-Koehler, Karin
    Vehling-Kaiser, Ute
    Schulze, Manfred
    Truckenbrodt, Juergen
    Goebeler, Mariele
    Mittermueller, Johann
    Bosse, Daniel
    Szukics, Borika
    Grundeis, Marc
    Zwingers, Thomas
    Giessen, Clemens
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 206 - 214
  • [37] Phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer after prior exposure to infusional 5-FU based chemotherapy.
    Schöffski, P
    Harstrick, A
    Kirchner, H
    Trenn, G
    Bokemeyer, C
    Preusser, P
    Achterrath, W
    Deub, B
    Wilke, H
    ANNALS OF ONCOLOGY, 2000, 11 : 44 - 44
  • [38] Irinotecan (CPT-11) in 5-FU pretreated advanced colorectal cancer: Results in 174 expanded access patients
    Iveson, T
    Eggleton, SPH
    Hickish, T
    Cunningham, D
    Maughan, T
    Harper, P
    ANNALS OF ONCOLOGY, 1998, 9 : 36 - 37
  • [39] Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer
    Chester, JD
    Dent, JT
    Wilson, G
    Ride, E
    Seymour, MT
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 235 - 237
  • [40] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
12345